Location History:
- Heidelberg, DE (2022)
- Munich, DE (2018 - 2023)
Company Filing History:
Years Active: 2018-2023
Title: Steffen Runz: Innovator in Antibody Development
Introduction
Steffen Runz is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 4 patents, his work focuses on addressing critical medical conditions through innovative solutions.
Latest Patents
Among his latest patents, Steffen Runz has developed antibodies targeting Glycoprotein VI. This patent provides antibodies or antibody fragments specific for GPVI, which are useful for the treatment or prophylaxis of GPVI-related disorders, such as thrombotic or vascular disorders. Another notable patent involves humanized antibodies for CD3. This invention offers humanized antibodies that specifically bind to CD3 with optimized affinity, inducing T cell-mediated killing of tumor-related target antigen high-expressing cells while maintaining limited activity on low-expressing cells. Additionally, this patent includes bispecific antibodies that bind to both human CD3 and tumor-related antigens, along with methods for generating these antibodies for various applications.
Career Highlights
Steffen Runz has worked with leading companies in the biotechnology sector, including Morphosys AG and Novartis AG. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects, further enhancing his expertise in antibody technology.
Collaborations
Throughout his career, Steffen has collaborated with talented professionals, including Julia Neugebauer and Kerstin Uhland. These partnerships have contributed to the advancement of his research and the successful development of innovative therapeutic solutions.
Conclusion
Steffen Runz is a distinguished inventor whose work in antibody development has the potential to transform treatment options for various medical conditions. His innovative patents and collaborations reflect his commitment to advancing biotechnology and improving patient outcomes.